Clinical Trial Update: Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study

View source ↗

Summary

The CLariTI study, sponsored by LimFlow, Inc., completed evaluation of the natural progression of high-risk chronic limb-threatening ischemia in patients with p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Limb-threatening Ischemia
• Peripheral Artery Disease

Drugs mentioned

• LimFlow System

Snippet

Sponsor: LimFlow, Inc. | Conditions: Critical Limb Ischemia, Peripheral Artery Disease | Status: COMPLETED